En direct

Le Centre de Recherche en Cancérologie de Marseille fête ses 50 ans ! -

Sep 2017 Oncotarget

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory locally advanced breast cancers.

Auteurs

Monneur A, Goncalves A, Gilabert M, Finetti P, Tarpin C, Zemmour C, Extra JM, Tallet A, Lambaudie E, Jacquemier J, Houvenaeghel G, Boher JM, Viens P, Bertucci F

Résumé

Inflammatory breast cancer (IBC) is a very aggressive form of breast cancer, as compared to locally advanced breast cancer (LABC). Neoadjuvant chemotherapy followed by surgery is the standard treatment in both cases. Whether IBC is less chemosensitive than LABC remains unclear. We retrospectively compared the rate of pathological complete response (pCR) to neoadjuvant chemotherapy in IBC and LABC.

Lire l‘article